Kaletra

Lopinavir, the active ingredient in Kaletra, is a protease inhibitor presented as a tablet for oral use. It is combined with ritonavir, a pharmacokinetic enhancer, to treat HIV-1 infection in both adults and children by blocking viral protease activity and preventing the formation of mature infectious virions. This fixed‑dose combination allows effective suppression of viral replication and supports immune recovery when used as part of antiretroviral therapy.

GNH USA supplies Kaletra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kaletra is an antiretroviral protease inhibitor used to manage HIV‑1 infection.

- HIV‑1 infection in adults: suppresses viral load and helps restore immune function. - HIV‑1 infection in children: provides effective viral suppression and supports growth and development. - HIV‑1 infection in treatment‑experienced patients: offers an alternative regimen when resistance to other agents is present.

Kaletra may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Diarrhea: frequent loose stools, sometimes leading to dehydration. - Nausea: feeling of sickness, may be accompanied by vomiting. - Headache: mild to moderate pain in the head region. - Elevated triglycerides: increase in blood lipid levels.

Serious or Rare Side Effects: - Hepatotoxicity: liver enzyme elevations or hepatitis. - Pancreatitis: inflammation of the pancreas with abdominal pain. - Severe allergic reactions: rash, itching, swelling, or anaphylaxis. - QT prolongation: cardiac rhythm disturbance that may lead to arrhythmia.

When prescribing Kaletra, clinicians should consider several precautionary measures to ensure safe use. - Baseline liver function: assess hepatic enzymes before initiating therapy. - Monitor lipid profile: check triglycerides and cholesterol regularly during treatment. - Assess for drug resistance: evaluate virologic response and consider resistance testing if viral load does not decline. - Use in pregnancy: prescribe only if benefits outweigh risks, as category B3. - Concomitant medications: review for potential CYP3A interactions and adjust doses as needed. - Store at ambient temperature: keep tablets below 25°C in the original container, protected from moisture.

Kaletra interacts with several medicines, requiring careful management of co‑administered drugs.

Major Interactions (Avoid): - Strong CYP3A inducers (e.g., rifampicin, carbamazepine, St. John’s wort): may markedly reduce lopinavir levels. - Certain antiarrhythmics (e.g., amiodarone, quinidine): can increase risk of cardiac toxicity. - Protease inhibitor boosters (e.g., other ritonavir‑containing regimens): may cause excessive drug exposure.

Moderate Interactions (Monitor Closely): - HMG‑CoA reductase inhibitors (statins such as simvastatin, lovastatin): increased risk of myopathy. - Sedatives and benzodiazepines: enhanced central nervous system depression. - Oral contraceptives: reduced hormonal efficacy, consider alternative contraception.